Eli Lilly

Healthcare

Novo Nordisk Seeks to Expand Liver Disease Treatments in $5.2B Deal for Bay Area Biotech

Photo via Ritzau Scanpix/Sipa USA/Newscom

The acquisition comes as new CEO Mike Doustdar tries to revive once meteoric growth that has come crashing down to earth this year.

2 min read

Photo via imageBROKER/Rupert Oberh�user/Newscom

Healthcare

Pfizer’s Drug Price Deal with White House Gives Big Pharma a Booster Shot

A 2024 RAND study found that US drug prices are 278% higher than in 33 other developed countries in the OECD.

2 min read
Photo via James Black/Icon Sportswire DHN/James Black/Icon Sportswire/Newscom

Healthcare

Eli Lilly Upstages Novo Nordisk in Obesity Pill Face-Off

Both companies have been desperate to innovate beyond their current injectable GLP-1 weight-loss drugs for a while now.

1 min read
Photo via Mu Yu / Xinhua News Agency/Newscom

Healthcare

China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington

China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.

2 min read

Healthcare

Lung Disease Breakthrough Boosts United Therapeutics — and its Rivals

Photo by Robina Weermeijer via Unsplash

About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.

2 min read

Healthcare

Novo Nordisk Backs Away From Hims & Hers Partnership

Photo via Abaca Press/Blondet Eliot/Abaca/Sipa USA/Newscom

Novo and Hims’ April team-up turned the two firms from competitors into collaborators at just the right moment.

2 min read

Healthcare

Hims & Hers Struggles After the FDA Puts a Ticking Clock on its Weight-Loss Drug

Photo by Chemist4U via CC BY-SA 2.0

Now that semaglutide’s no longer in shortage territory, the FDA said drug-makers have 90 days to wrap up production of their Novo knockoffs.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.